New weekly shot aims to beat leading drug in diabetes and weight loss battle
NCT ID NCT06184568
Summary
This study is testing if a new weekly injection called IBI362 works better than an existing drug, semaglutide, for people with early type 2 diabetes and obesity. About 349 Chinese adults will receive one of the two injections for 32 weeks to see which one helps more people reach healthy blood sugar levels and lose a significant amount of weight. The main goal is to see if IBI362 helps a higher percentage of people achieve both good blood sugar control and at least 10% weight loss.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100010, China
Conditions
Explore the condition pages connected to this study.